Skip to content
10-Q

Quarterly Report

CymaBay Therapeutics, Inc.

0001193125-23-144944

← back to feed
Filed
May 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Apr 30, 2023 97.51M sh
Shares Diluted Q1 2023 · Mar 31, 2023 97.97M sh
Shares Diluted Q1 2023 · Mar 31, 2022 87.8M sh
Capex Q1 2023 · Mar 31, 2023 $195K
Capex Q1 2023 · Mar 31, 2022 $0
Operating Cash Flow Q1 2023 · Mar 31, 2023 $6.43M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$25.36M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $59.15M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $20.29M
Stockholders Equity Q1 2023 · Mar 31, 2023 $104.19M
Stockholders Equity Q1 2023 · Dec 31, 2022 $36.15M
Stockholders Equity Q1 2023 · Mar 31, 2022 $107.38M
Stockholders Equity Q1 2023 · Dec 31, 2021 $132.94M
Current Liabilities Q1 2023 · Mar 31, 2023 $46.5M
Current Liabilities Q1 2023 · Dec 31, 2022 $15.44M
Total Liabilities Q1 2023 · Mar 31, 2023 $141.13M
Total Liabilities Q1 2023 · Dec 31, 2022 $105.7M
Current Assets Q1 2023 · Mar 31, 2023 $242.72M
Current Assets Q1 2023 · Dec 31, 2022 $138.07M
Total Assets Q1 2023 · Mar 31, 2023 $245.32M
Total Assets Q1 2023 · Dec 31, 2022 $141.85M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.29
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.32
Eps Basic Q1 2023 · Mar 31, 2023 −$0.29
Eps Basic Q1 2023 · Mar 31, 2022 −$0.32
Sga Expense Q1 2023 · Mar 31, 2023 $8.32M
Sga Expense Q1 2023 · Mar 31, 2022 $6.09M
Rd Expense Q1 2023 · Mar 31, 2023 $18.55M
Rd Expense Q1 2023 · Mar 31, 2022 $18.42M
Net Income Q1 2023 · Mar 31, 2023 −$28.78M
Net Income Q1 2023 · Mar 31, 2022 −$27.77M
Operating Income Q1 2023 · Mar 31, 2023 −$26.88M
Operating Income Q1 2023 · Mar 31, 2022 −$24.5M
Stock Issued Q1 2023 · Jan 23, 2023 11.82M sh